Medicilon is honored as TOP 20 R&D CRO Enterprises in China

著者：medicilon   アップロード：2020-09-21  閲読回数：

Chongqing, September 10, 2020 – 2020 Conference on High Quality Development of Healthcare Industry & the Fifth China Pharmaceutical R&D and Innovation Summit was held successfully. Attendees, including KOL and experts from pharmaceutical regulatory system, as well as enterprise executives and elites studying strategic management, project approval, investment evaluations and business trading for ages, shared and discussed topics concerning formulation development and pharmaceutical innovation.

During the conference, the sponsor announced six industry ranking lists, including 2020 TOP 20 R&D CRO Enterprise in China. Medicilon was nominated and ranked the 4th place on the list. This honor showed approval of progress and development Medicilon had made in the past, meanwhile motivating Medicilon to provide better services in the future.

上の：Medicilon won two awards at The 15th Award of competitive and trustworthy listed companies.

下に：Medicilon MetID Services